Intravitreal ranibizumab, intravitreal ranibizumab with photodynamic therapy (PDT), and intravitreal triamcinolone with PDT for the treatment of retinal angiomatous proliferation.
Atul Kumar
AK
Sahu
Raja
R
Narayanan
D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized; D004359:Drug Therapy, Combination; D005451:Fluorescein Angiography; D005938:Glucocorticoids / Q000008:administration & dosage* / Q000009:adverse effects; D006391:Hemangioma / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D006801:Humans; D007267:Injections; D010778:Photochemotherapy / Q000009:adverse effects; D000069579:Ranibizumab; D012160:Retina / Q000187:drug effects / Q000473:pathology; D019572:Retinal Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D013997:Time Factors; D016896:Treatment Outcome; D014221:Triamcinolone / Q000008:administration & dosage* / Q000009:adverse effects; D014792:Visual Acuity / Q000187:drug effects; D014822:Vitreous Body
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D005938:Glucocorticoids; D014221:Triamcinolone; D000069579:Ranibizumab